Clinical Research Directory
Browse clinical research sites, groups, and studies.
3 clinical studies listed.
Filters:
Tundra lists 3 Overweight Subject clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT07866365
Longitudinal Tracking Study on the Path Evolution of College Students' Proactive Health Behaviors Based on the "Environment-Psychology-Behavior" Three-Dimensional Coupling Model
In the post-pandemic era, the Healthy China 2030 Plan Outline and the Healthy Zhejiang 2030 Action Plan have promoted the upgrading of health management. However, the current weight loss intervention methods in colleges and universities are relatively single, mostly focusing on exercise or dietary guidance, while ignoring the synergistic effect of psychology and environment, resulting in a weight regain rate of over 40%. Moreover, the overweight rate of college students in China reaches 14.0%, and obesity and psychological problems form a negative cycle, which hinders the promotion of the whole-life-cycle health management. This project targets the 2025-level slightly overweight college freshmen with a BMI of 23.9-27.9, integrating the Self-Determination Theory (SDT) and the Ecosystem Theory.
Gender: All
Updated: 2026-10-08
1 state
NCT07331389
A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin
The purpose of this study is to characterize the drug-drug intereaction of HDM1002 and metformin, empagliflozin, midazolam, valsartan, and warfarin in overweight/obese adult subjects. The safety and tolerability of HDM1002 with metformin, empagliflozin, midazolam, valsartan, and warfarin when given separately or together will also be evaluated
Gender: All
Ages: 18 Years - 45 Years
Updated: 2026-01-09
NCT06601517
A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.
The purpose of this study is to characterize the effect of HDM1002 on the PK of single dose of repaglinide, atorvastatin, digoxin and rosuvastatin in healthy adult subjects. The safety and tolerability of HDM1002 with repaglinide, atorvastatin, digoxin and rosuvastatin when given separately or together will also be evaluated.
Gender: All
Ages: 18 Years - 45 Years
Updated: 2024-09-23